Global pharmaceutical R&D continues at steady pace; Fitch report

17 December 2010

The US Food and Drug Administration and the European Medicines Agency approved six new molecular entities (NMEs) during the third quarter 2010, of which, six were developed or licensed by Fitch Ratings-rated pharmaceutical developers, according to the agency's new Global Pharmaceutical R&D Pipeline report. In addition, Japan's Ministry of Health, Labor and Welfare cleared six new medicines developed by Fitch-rated pharmaceutical companies for sale in the region.

To date, approximately one-half of the original 22 new therapeutics have been filed as planned in 2010, while there have been three drug project cancellations and six extensions to original filing goals. In the third quarter, the applications for four NMEs were filed to drug regulators in Europe or the USA, keeping a modest yet steady pace throughout the year of around three per quarter.

But 12 projects terminated

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

More ones to watch >